Observational, Prospective
Conditions
Keywords
breast cancer, HER2 positive, next generation sequencing, trastuzumab, neoadjuvant chemotherapy
Brief summary
To explore the genetic background of patients with HER2 positive breast cancer that benefit from trastuzumab combined with neoadjuvant chemotherapy, identify clinically actionable mutations that associated with trastuzumab resistance or drug efficacy, we designed this Observational phase II trial. The primary endpoint is genetic profile of HER2+ breast cancer patients treated with trastuzumab combined neoadjuvant chemotherapy. Secondary endpoints included pathological complete response (pCR) rate and safety.
Detailed description
Currently, patients with stage II-III breast cancer still accounts for a large population in China, and neoadjuvant therapy is considered the standard treatment for them. The pathological complete response (pCR) rate takes for an indicator for regimens efficacy, and the achievement of pCR after neoadjuvant chemotherapy is associated with favorable outcomes including disease-free survival and overall survival. HER2+ breast cancer represents an invasive and poor prognosis subtype, and the efficacy of neoadjuvant therapy for these patients has been greatly augmented by the addition of trastuzumab. However, more than 50% of HER2+ breast cancer patients treated with trastuzumab combined neoadjuvant chemotherapy cannot achieve pCR, even experience primary drug resistance and rapid disease progression. Therefore, to explore the genomic features of the population that benefited from trastuzumab combined with chemotherapy is of great significance for personalized treatment of HER2+ breast cancer, aiming to avoid overtreatment and identify clinically actionable mutations for future therapy instructions.
Interventions
DRUGTrastuzumab+TP
Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
Sponsors
OrigiMed
Hebei Medical University Fourth Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* women aged 18-70 years old at the time of diagnosis of primary breast cancer * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 * Stage III breast cancer according to the 7th Edition of Cancer staging Manual of American Joint Committee on Cancer (AJCC) * full assessment of ER, PR and HER2 status of primary tumor in accordance with the American Society of Clinical Oncology (ASCO) guidelines * pathological diagnosis and all courses of treatment confirmed
Exclusion criteria
* any known metastatic disease, by physical exam or by imaging studies such as computed tomography (CT)/magnetic resonance imaging (MRI), at the time of study entry * any previous exposure to chemotherapy, radiotherapy, or endocrine therapy * left ventricular ejection fraction (LVEF) \< 55% by Echocardiogram (ECHO) or multigated acquisition scan (MUGA) or significant clinical symptoms or signs of heart failure * major organ dysfunction, inclusive of bone marrow, renal, liver and hepatic function, that would prohibit patients from receiving standard chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| genetic profile sequenced by a pan-cancer gene panel | 1 year | analyze the genetic profile of HER2+ breast cancer patients treated with trastuzumab combined neoadjuvant chemotherapy by targeted next generation sequencing on a pan-cancer gene panel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pCR | 1 year | The pathological complete response (pCR) rate of patients treated with trastuzumab neoadjuvant chemotherapy. |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 year | The incidence of adverse events of patients treated with trastuzumab neoadjuvant chemotherapy, including Cardiac toxicity, leukopenia, etc. |
Countries
China
Contacts
Primary ContactYunjiang Liu, MD, PhD
Outcome results
None listed